

**AMENDMENTS TO THE CLAIMS:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

1.-179. (Canceled).

180. (New) A method of administering a beneficial substance to a human or animal subject, said method comprising subcutaneously implanting an implant comprising a resorbable mesoporous silicon carrier material having a beneficial substance associated therewith, wherein the mesoporous silicon carrier material is corrodible by mammalian subcutaneous physiological fluids.

181. (New) A method according to claim 180, wherein the mesoporous silicon has a porosity between about 2% and 80%.

182. (New) A method according to claim 180, wherein the mesoporous silicon has a porosity between about 4% and 50%.

183. (New) A method according to claim 180, wherein the mesoporous silicon has a porosity of about 30%.

184. (New) A method according to claim 180, wherein the beneficial substance is delivered over an interval of between about one month and one year.

185. (New) An implant according to claim 180, wherein the implant has a largest dimension  $x$ , wherein  $0 < x \leq 2\text{mm}$ .

186. (New) A method according to claim 180, wherein the mesoporous silicon comprises an element which has been impregnated at a concentration between 1 and 90 atomic percent at a depth, from the surface of the sample, between  $0.35\mu\text{m}$  and  $1000\mu\text{m}$ .

187. (New) A method according to claim 180, wherein the element is present at a concentration between 30 $\mu$ m and 1000 $\mu$ m.

188. (New) A method according to claim 186, wherein the element is phosphorus.

189. (New) A method according to claim 180, wherein the beneficial substance comprises an anti-cancer substance.